240 related articles for article (PubMed ID: 21912334)
1. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
2. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
4. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
5. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
[TBL] [Abstract][Full Text] [Related]
7. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
[TBL] [Abstract][Full Text] [Related]
8. Drug plasma monitoring in CML and GIST: A case-based discussion.
Egorin MJ; Mauro MJ; Trent JC
Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S3-11. PubMed ID: 20099379
[TBL] [Abstract][Full Text] [Related]
9. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
11. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
12. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison.
Awidi A; Salem II; Najib N; Mefleh R; Tarawneh B
Leuk Res; 2010 Jun; 34(6):714-7. PubMed ID: 19744707
[TBL] [Abstract][Full Text] [Related]
13. Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
Iqbal Z; Elliott M; Watson DG; Holyoake T; Jørgensen H
Pak J Pharm Sci; 2011 Jul; 24(3):285-91. PubMed ID: 21715261
[TBL] [Abstract][Full Text] [Related]
14. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
16. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
Gandia P; Arellano C; Lafont T; Huguet F; Malard L; Chatelut E
Cancer Chemother Pharmacol; 2013 Feb; 71(2):531-6. PubMed ID: 23183914
[TBL] [Abstract][Full Text] [Related]
17. Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.
Arellano C; Gandia P; Lafont T; Jongejan R; Chatelut E
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 907():94-100. PubMed ID: 23000741
[TBL] [Abstract][Full Text] [Related]
18. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Roth O; Spreux-Varoquaux O; Bouchet S; Rousselot P; Castaigne S; Rigaudeau S; Raggueneau V; Therond P; Devillier P; Molimard M; Maneglier B
Clin Chim Acta; 2010 Feb; 411(3-4):140-6. PubMed ID: 19853594
[TBL] [Abstract][Full Text] [Related]
19. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
20. Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
Ajimura TO; Borges KB; Ferreira AF; de Castro FA; de Gaitani CM
Electrophoresis; 2011 Jul; 32(14):1885-92. PubMed ID: 21710556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
